Hodgkin's Disease in Denmark: A National Clinical Study by the Danish Hodgkin Study Group, LYGRA

Nordentoft, A. M.; Pedersen‐Bjergaard, Jens; Brincker, H; Andersen, Erik André; Pedersen, Morten Videbæk; Nielsen, Janni; Jensen, Kenneth; Nissen, Nis I.; Jensen, T. Skov; Videbaek, A; Jensen, Mogens Krogh; Walbom-Jørgensen, S.

doi:10.1111/j.1600-0609.1980.tb01591.x

Cited by 27 publications

(1 citation statement)

References 25 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study population consisted of 142 patients treated for Hodgkin's disease, 54 with mantle-field irradiation, 26 with 6 months of chemotherapy and 62 with mantle-field irradiation followed by chemotherapy (combined modality therapy). All the patients had participated in randomized trials, either LYGRA (15) or CALGB protocols (16,17,18). We only included patients in first remission and excluded patients who had received irradiation to the lungs outside the mantle-field, who had lung parenchymal Hodgkin involvement, or had a history of chronic lung disease or congestive heart failure prior to the treatment.…”

Section: Methodsmentioning

confidence: 99%

Late effects on pulmonary function of mantle‐field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease

Jensen¹,

Carlsen²,

Groth³

et al. 1990

European J of Haematology

View full text Add to dashboard Cite

The aim of the present study was to assess late pulmonary sequelae after treatment for Hodgkin's disease with various treatment modalities. Pulmonary function was studied in 142 patients per median 8 years after treatment for Hodgkin's disease with mantle‐field irradiation (54 patients), chemotherapy (26 patients) or mantle‐field irradiation followed by chemotherapy (62 patients). Mantle‐field irradiation was associated with a primary obstructive and minor restrictive lung function impairment, whereas chemotherapy and combined modality therapy were associated with a restrictive lung function impairment. The number of patients with impaired lung function and the number of patients with complaints of dyspnea, however, were almost the same in the three treatment groups. 5% of the 142 patients had a pathologically low total lung capacity, i.e. values less than 2 standard deviations below predicted values. Pathologically low values of forced vital capacity and forced expiratory volume in 1 second were seen in 33% and 27% of the patients. 33% of the smokers (n = 80) had a pathologically low diffusion capacity in contrast to 8% of the non‐smokers (n = 62). Dyspnea on exertion was present in 24% of the 142 patients and was more frequent among patients with pulmonary functional abnormalities. In conclusion, late pulmonary sequelae after treatment for Hodgkin's disease do not provide a basis for choice between otherwise equally effective treatment regimes.

show abstract

Section: Methodsmentioning

confidence: 99%

Late effects on pulmonary function of mantle‐field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease

Jensen¹,

Carlsen²,

Groth³

et al. 1990

European J of Haematology

View full text Add to dashboard Cite

show abstract

Prognostic factors in hodgkin's disease with special reference to age

Wedelin

Björkholm

Biberfeld

et al. 1984

Cancer

View full text Add to dashboard Cite

A series of 182 patients with Hodgkin's disease, diagnosed between January 1973 and December 1978 was used to identify prognostic factors with special reference to age. There were 118 men and 64 women (mean age, 47 years; r = 15–92). During the same period 57 elderly patients who were never referred, were reported to the Local Cancer Registry. The diagnosis had been established shortly before death or at autopsy. The 182 patients under study were evenly distributed in Stages I‐IV. Nodular sclerosis (38%) and mixed cellularity (38%) were the most common histologic subtypes. The 5‐year survival probability estimate was 28% in patients above 50 years as compared to 74% in the remainder. Survival was significantly better in patients with Stage I‐II disease and lymphocyte predominance/nodular sclerosis histopathology. Age was the main prognostic factor in the whole series as well as in patients older than 50 years. However, in young patients advanced clinical stage and B‐symptoms were related to a poor prognosis. Biologic indicators such as ESR, hemoglobin and albumin were intimately linked to the extent of disease and did not add prognostic information besides that given by the clinical stage. It is concluded that the prognosis in elderly remains poor and appears to be partly unrelated to those factors which determine the prognosis in the young, assumingly reflecting a depressed host‐response and/or a decreased tolerance to intensive treatment. Cancer 53:1202‐1208, 1984.

show abstract

Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk

Franklin

Paus

Pluetschow

et al. 2005

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Hodgkin's Disease in Denmark: A National Clinical Study by the Danish Hodgkin Study Group, LYGRA

Cited by 27 publications

References 25 publications

Late effects on pulmonary function of mantle‐field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease

Late effects on pulmonary function of mantle‐field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease

Prognostic factors in hodgkin's disease with special reference to age

Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk

Contact Info

Product

Resources

About